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Recruitment of Stem and Progenitor Cells
from the Bone Marrow Niche Requires
MMP-9 Mediated Release of Kit-Ligand
nals that maintain the stem cell niche and regulate the
repopulation of stem cells. Mice with steel (Sl/Sld) muta-
tion produce deficiency in membrane Kit-ligand (KitL,
stem cell factor) in the tissue microenvironment, im-
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stem cells are in contact with BM stromal cells, including4 Department of Anatomy
osteoblasts, and are maintained in G0 phase of cell cycleUniversity of California, San Francisco
(Cheng et al., 2000), while a small fraction is in S or G2/MHSW 1321
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two compartments is dictated by the bioavailability ofSan Francisco, California 94143
stem cell-active cytokines, which are bound to the extra-
cellular matrix or tethered to the membrane of stromal
cells. Stress, such as BM ablation by cytotoxic agents,Summary
switches on sequences of events where HSCs are re-
cruited from their niches to reconstitute hematopoiesis.Stem cells within the bone marrow (BM) exist in a
Treatment with cell cycle cytotoxic agents, includingquiescent state or are instructed to differentiate and
5-fluorouracil (5-FU), depletes cycling hematopoieticmobilize to circulation following specific signals. Ma-
cells. Within 3 days after myelosuppressive stress, thetrix metalloproteinase-9 (MMP-9), induced in BM cells,
sequential release of chemokines and cytokines thatreleases soluble Kit-ligand (sKitL), permitting the
promote stem cell migration into a permissive microen-transfer of endothelial and hematopoietic stem cells
vironment support proliferation, differentiation, and mo-(HSCs) from the quiescent to proliferative niche. BM
bilization to the circulation. By day 10 after 5-FU treat-ablation induces SDF-1, which upregulates MMP-9 ex-
ment, myeloid, erythroid, lymphoid, and megakaryocyticpression, and causes shedding of sKitL and recruit-
cell lineages repopulate the BM. In parallel, the mobi-ment of c-Kit stem/progenitors. In MMP-9/ mice,
lized stem cells can be incorporated into specific organsrelease of sKitL and HSC motility are impaired, re-
or, in the case of HSCs, expand in extramedullary sitessulting in failure of hematopoietic recovery and in-
and recirculate back to the BM to replenish the stemcreased mortality, while exogenous sKitL restores he-
and progenitor pool.matopoiesis and survival after BM ablation. Release
HSCs, and other stem cells including cardiac (Orlic etof sKitL by MMP-9 enables BM repopulating cells to
al., 2001), endothelial (Peichev et al., 2000), and epithelialtranslocate to a permissive vascular niche favoring
cells express c-Kit, the receptor for KitL, suggesting
differentiation and reconstitution of the stem/progeni-
that a common signaling cascade may govern their pro-
tor cell pool. liferation and recruitment. Mutations in KitL or c-Kit pro-
duce defects in germ cell and melanocyte development,
Introduction impairment of hematopoiesis, and increased sensitivity
to radiation and chemotherapy (Huang et al., 1992).
Stem cells are localized in a microenvironment known These observations suggest that KitL plays a key role
as the stem cell “niche,” where they are maintained in for maintaining and reconstituting the stem cell pool in
an undifferentiated and quiescent state. These niches adult mice.
are critical for regulating the self-renewal and cell fate Local secretion of proteases may alter the stem cell-
decisions, yet molecular mechanisms governing survival stromal cell interaction. The proteolytic cleavage of vas-
and maintenance of quiescent stem cells in these spe- cular cell adhesion molecule-1, expressed by BM stro-
cialized environments and why and how these cells are mal cells, is triggered by the degranulation of neutrophils
recruited to exit these niches are not well studied. In in the BM after granulocyte colony stimulating factor
Drosophila, germ cells lost by normal or induced differ- (G-CSF) administration and may be an essential step
entiation are efficiently replaced within their niches (Xie contributing to the mobilization of hematopoietic pro-
and Spradling, 2000). Stromal cells provide extrinsic sig- genitors (Levesque et al., 2001). Matrix metalloprotein-
ases (MMPs) promote the release of extracellular matrix-
bound or cell-surface-bound cytokines (Vu and Werb,5 Correspondence: srafii@med.cornell.edu
6 These authors contributed equally to this work. 2000), such as vascular endothelial growth factor
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Figure 1. MMP-9 Is Induced in BM Cells after
BM Ablation
(A and B) MMP-9/ and MMP-9/ mice re-
ceived a single dose of 5-FU i.v. BM cells
obtained at different time points after 5-FU
injection were cultured in serum-free medium
overnight. BM cell supernatants were as-
sayed for pro-MMP-9 by Western blot (A) and
active MMP-9 by gelatin zymography (B). Mo-
lecular weight (kDa) are shown (n 5/group).
(C) Immunohistochemistry of BM sections
three days after 5-FU injection for pro-
MMP-9, which shows brown staining of stro-
mal and hematopoietic elements in MMP-
9/ mice (c and d), but not in MMP-9/ mice
(a and b); magnification 100, (a and c)
and 400 (b and d).
(VEGF), which then can regulate angiogenesis (Bergers 1982). In wild-type mice, BM hematopoietic and stromal
cells expressed MMP-9 three days after treatment withet al., 2000) or osteoclast recruitment (Engsig et al.,
2000). Accordingly, we asked whether MMPs contribute 5-FU (Figure 1C). These data suggest that both pro-
MMP-9 and MMP-9 are upregulated in BM cells afterto the release of stem cell-active cytokines following
stress that shifts stem cells and progenitors from a qui- myelosuppression.
escent to a proliferative niche essential to reconstitute
the stem cell pool and hematopoietic recovery. MMP-9/ Mice Show Delayed Hematopoietic
Recovery Following 5-FU Treatment
To understand the role of MMP-9 in promoting HSCResults
recruitment and hematopoietic recovery after BM sup-
pression, we used MMP-9-deficient mice. Under steady-BM Suppression Induces MMP-9 Expression
in BM Cells state conditions, adult MMP-9/ and MMP-9/ mice
have similar peripheral white blood cell (WBC) countsWhile BM suppression with 5-FU results in apoptosis of
actively cycling HSCs and progenitor cells, it does not and both became leukopenic within six days after 5-FU
treatment (Figure 2A). However, in 5-FU-treated MMP-affect HSCs in G0 of cell cycle. This model is ideal for
studying factors that promote recruitment of HSCs dur- 9/ mice, the recovery of WBC (Figure 2A) and platelets
(data not shown) was delayed by an additional 8 days.ing hematopoietic reconstitution. We found an increase
in pro-MMP-9 (Figure 1A) and active MMP-9 (Figure 1B), This prolonged delay in hematopoietic recovery resulted
in the death of 72% (n  16, p  0.001) of 5-FU-treatedbut not tissue inhibitor of metalloproteinases (TIMP-1)
in supernatants of BM cells of MMP-9 wild-type animals MMP-9/ mice, while all of MMP-9/ mice survived
(Figure 2B). These data suggest that MMP-9 plays athree days after 5-FU treatment. In BM cells of untreated
animals, there was a small amount of MMP-9 (Figure critical role in accelerating hematopoietic reconstitution.
Cell cycling, motility, and differentiation of HSCs are1B) derived from resident neutrophils (Murphy et al.,
MMP-9 Regulates the Stem Cell Microenvironment
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Figure 2. Delayed Hematopoietic Recovery and Increased Mortality in MMP-9/ Mice after Myelosuppression
(A and B) MMP-9/ and MMP-9/ mice (n  16) received a single i.v. dose of 5-FU.
(A) WBC counts were quantified by a Neubauer chamber.
(B) Survival of 5-FU-treated mice was assessed daily (n  16).
(C and D) Mice treated with 5-FU were sacrificed at different time points. Percentage/total number of Sca-1 (n  5) and LinSca-1c-Kit
(n  7) cells, isolated by a combination of magnetic cell isolation (MACS) and flow cytometry (FACS), in S phase was determined for DNA
content after propidium iodide staining. The total number of Sca-1 cells in S phase was higher in MMP-9/ as compared to MMP-9/ mice
(2.2  0.05 versus 1.0  0.03  105/femur on day 6 and 11.5  0.3 versus 2.1  0.04  105 /femur on day 10, respectively). All values are
given as mean  SEM. *p  0.01, **p  0.001.
accelerated during hematopoietic recovery after BM ab- zone (O),” followed by a shift of cells moving toward the
blood vessel-enriched “vascular zone (V)” on day 10lation. We next determined whether the impaired hema-
topoietic recovery of HSCs in MMP-9/ mice was due (Figure 3B). However, in the BM of MMP-9/ animals,
there was a paucity of hematopoietic cell clusters into an alteration in the stem/progenitor cell cycling status.
Hematopoietic cells phenotypically marked as LinSca- both the osteoblastic and vascular zones, even on day
10 after 5-FU treatment. By day 10, the proportion of1c-Kit comprise a large percentage of long-term re-
populating HSCs (Cheshier et al., 1999). Under steady- differentiated CD11bGr-1 myeloid (Figure 3A) and
vWF megakaryocytic precursor cells (Figure 3C) in thestate conditions, the percentage and the total number
of Sca-1 (Figure 2C) and LinSca-1c-Kit cells (Figure BM of 5-FU-treated MMP-9/ mice was dramatically
reduced. The impaired recruitment of repopulating stem2D) in S phase of cell cycle were not significantly differ-
ent in MMP-9/ and MMP-9/ mice. However, follow- and progenitor cells into the vascular zone and the lack
of differentiation into myeloid and megakaryocytic lin-ing 5-FU myeloablation, the number of these cells enter-
ing S phase of cell cycle was impaired in MMP-9/ eages in MMP-9/ mice led us to hypothesize that
MMP-9 may exert its effects through the release of amice. These data suggest that although during steady-
state hematopoiesis there is no difference in the number stem cell-active cytokine.
of cycling repopulating cells, in the recovery phase after
myelosuppression, lack of MMP-9 results in a dimin-
ished recruitment of cycling cells leading to profound Release of Soluble KitL (sKitL) Is Impaired
in MMP-9/ Mice after BM SuppressionBM hypocellularity.
Among the known stem cell-active chemokines and cy-
tokines, KitL conveys signals that modulate survival,Restoration of Myeloid and Megakaryocytic
Lineages Is Impaired in MMP-9/ Mice adhesion, and motility of c-Kit HSC and endothelial
cells. sKitL is expressed as a membrane (mKitL) formOn day 6 after 5-FU treatment, in MMP-9/ mice, BM
cellularity increased and hematopoietic cell clusters and can be cleaved to a soluble form (sKitL) (Huang et
al., 1992). Indeed, plasma levels of sKitL increased 3-foldwere seen in close contact to the bone “osteoblastic
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Figure 3. Recruitment and Differentiation of Hematopoietic Cells Are Impaired in MMP-9/ Mice
MMP-9/ and MMP-9/ mice were treated with 5-FU and the hematopoietic recovery and the frequency and distribution of myeloid and
megakaryocytic precursor cells was evaluated by FACS (A) or immunohistochemistry (B and C).
(A) BM cells obtained from either MMP-9/ or MMP-9/ mice were stained for the myeloid markers CD11b-FITC and Gr-1-PE and analyzed
by FACS (left panel). Absolute number of CD11b/Gr-1 BM cells per femur was calculated at different time points (right panel, n  6, *p 
0.01).
(B) H&E staining of femurs from mice after 5-FU treatment. Hematopoietic cell clusters can be detected in close contact to osteoblasts
(Osteoblastic zone, O) in the early phase of BM recovery. Over time, abundant clusters of proliferating hematopoietic cells are detected both
in the osteoblastic zone and in the vascular-enriched zone (Vascular zone, V) in wild-type animals. In contrast, there is a striking paucity of
hematopoietic cell clusters in the osteoblastic and the vascular zone in 5-FU-treated MMP-9/ mice.
(C) vWF staining (brown) of femurs at different time points following 5-FU treatment. vWF positive megakaryocytes increase during BM
recovery in MMP-9/ mice, but not in MMP-9/ mice (arrows; magnification 100) .
MMP-9 Regulates the Stem Cell Microenvironment
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Figure 4. MMP-9 Mediated Release of sKitL Enhances Hematopoietic Reconstitution
(A) MMP-9/ and MMP-9/ mice were injected i.v. with a single dose of 5-FU and the plasma obtained from peripheral blood (PB) was
assayed for sKitL by ELISA (p 0.05, n  6/group).
(B) Confluent MS-5 murine stromal cells, which express mKitL, were treated with recombinant active MMP-9 or the MPI CGS 27023A for 24
hr.*p 0.001.
(C) MMP-9/ and MMP-9/ mice were injected i.v. on day 0 with a single dose of Ad vector encoding for sKitL (AdsKitL) or no transgene
(AdNull). PB was taken at indicated days (n  6/group). Injection of AdsKitL resulted in sKitL plasma levels of 5399  50 and 5126  102 pg/
ml on day 5 in MMP-9/ and MMP-9/ mice, respectively. PBMCs were stained for Sca-1 and c-Kit and analyzed by FACS.
(D) MMP-9/ and MMP-9/ mice were injected with recombinant sKitL from day 3–11 after 5-FU therapy (n  10/group). WBC counts were
determined at indicated time points.
(E) H&E staining of BM sections 4 days after 5-FU marrow suppression in MMP-9/ and MMP-9/ mice without (control) and with sKitL.
Magnification  200.
during the hematopoietic regeneration phase in MMP- compartment is more critical in providing bioactive
MMP-9 following myelosuppression, we developed chi-9/ mice, peaking at 6 days when there was active
proliferation in the BM. In contrast, baseline sKitL meric mice by transplanting BM cells from MMP-9/
mice into lethally irradiated MMP-9/ recipients re-plasma levels were very low in MMP-9/ mice and did
not increase following BM ablation (Figure 4A). These sulting in chimeric mice in which hematopoietic cells
are MMP-9 deficient. Transplantation and engraftmentdata suggest that MMP-9 promotes rapid release of
sKitL facilitating BM recovery. of BM from MMP-9/ into MMP-9/ mice resulted in
mice with MMP-9-deficient stroma (Supplemental Fig-Unstimulated BM stromal cells express both mKitL
and MMP-9 (Heinrich et al., 1993; Marquez-Curtis et al., ure S4a, available at http://www.cell.com/cgi/content/
full/109/5/625/DC1). As controls, MMP-9/ BM cells2001). Although MMP-9 was present at low levels in the
supernatants of the unstimulated murine BM stromal were transplanted into lethally irradiated MMP-9/mice
and MMP-9/ BM cells into lethally irradiatedcell line MS-5, which expresses mKitL, addition of re-
combinant MMP-9 rapidly promoted the release of MMP-9/ mice. All mice showed engraftment after 16
days as determined by WBC counts. The majority ofsKitL. This shedding was blocked by a synthetic metallo-
proteinase inhibitor (MPI; Figure 4B). These data sug- MMP-9/ recipients transplanted with either MMP-9/
or MMP-9/ BM or MMP-9/ recipients transplantedgest that MMP-9 can effectively promote the release of
sKitL from stromal cells. with MMP-9/ BM survived 5-FU myelosuppression.
As expected, high mortality was observed in the MMP-However, MMP-9 expression is upregulated in both
hematopoietic and stromal compartments of the BM 9/ group transplanted with MMP-9/ BM cells. These
data indicate that MMP-9 expressed either by stromalafter myeloablation (Figure 1C). To identify which cellular
Cell
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or hematopoietic cells is sufficient to support hemato- Chemokine-Induced Mobilization of BM
Repopulating Cells Is Impairedpoiesis after myelosuppression.
in MMP-9-Deficient Mice
Plasma elevation of SDF-1, VEGF, and G-CSF in
MMP-9/ mice, but not in MMP-9/ mice mobilizedExogenous sKitL Restores Hematopoietic
mature WBCs (Figures 6A–6C) and hematopoietic pro-Recovery and Mobilization in MMP-9/ Mice
genitors (CFU-Cs; Figure 6D). The mobilization of hema-Under steady-state conditions, elevated sKitL levels de-
topoietic cells into the circulation followed the kineticslivered by adenoviral vector expressing sKitL (AdsKitL)
of plasma elevation of these chemokines (Figures 6Aincreased WBC in both MMP-9/ and MMP-9/ mice
and 6B). We next determined if MMP-9 plays a role(Figure 4C). Progenitor mobilization determined by ei-
in mobilization of cells with repopulating capacity byther the frequency of mobilized Sca-1c-Kit cells (Fig-
transplanting peripheral blood mononuclear cellsure 4C) or colony-forming unit cells (CFU-Cs) in the pe-
(PBMCs) mobilized by G-CSF as the source of BM re-ripheral blood (Supplemental Figure S4b at above URL)
populating cells into lethally irradiated syngeneic mice.was enhanced in the MMP-9/mice after AdsKitL intro-
Mice transplanted with G-CSF-mobilized PBMCs har-duction.
vested from MMP-9/ mice 5 days after chemokineSince MMP-9 augments the release of sKitL, we next
treatment showed long-term donor cell engraftment andasked whether the delayed hematopoietic recovery
survival, whereas those transplanted with G-CSF-mobi-seen in MMP-9/ mice could be restored directly by
lized PBMCs from MMP-9/ mice died during the 20exogenous recombinant sKitL. Treatment of MMP-9/
days allowed for engraftment (Figure 6E). These datamice with recombinant sKitL following 5-FU treatment
show that MMP-9 plays a role in mobilization of BMresulted in rapid recovery of WBC (Figure 4D). In addi-
repopulating cells.tion, sKitL treatment following 5-FU BM suppression
The necessity of chemokine-induced mobilization onresulted in a rapid increase in BM cellularity and hemato-
MMP activity was confirmed by administrating a syn-poietic reconstitution in MMP-9/ mice (Figure 4E) and
thetic MPI in vivo, which also decreased WBC countsrestored survival of MMP-9/ mice (decreasing mortal-
and blocked chemokine-induced mobilization in MMP-ity to 17% compared to 72% observed in the PBS group,
9-competent mice (data not shown). Importantly, mobili-n  10 in each group). These data suggest that MMP-
zation of hematopoietic cells with short-term repopulat-
9 mediated release of sKitL is essential for promoting
ing potential (CFU-S) was completely blocked in MPI-
stem cell differentiation, accelerating hematopoietic re-
treated mice (Supplemental Figure S6a available at
constitution following BM ablation.
http://www.cell.com/cgi/content/full/109/5/625/DC1).
Lethally irradiated syngeneic mice transplanted with
SDF-1-, VEGF-, and G-CSF-mobilized PBMCs showed
Chemokines Released upon BM Suppression long-term engraftment in 55%, 40%, and 80% of these
Promote MMP-9 Expression mice, respectively (Supplemental Figures S6b, c, and d
But what regulates MMP-9? One clue came from the at above URL). Similar to MMP-9/ mice, transplanta-
observation that the chemokine stromal cell-derived tion of PBMCs from MPI-treated mice failed to reconsti-
factor-1 (SDF-1) increased after myelosuppression (Po- tute hematopoiesis in lethally irradiated recipients and
nomaryov et al., 2000). Plasma levels of SDF-1 increased all recipient mice died within 19 days.
following 5-FU treatment, peaking on day 8 (Figure 5A).
These data suggest that rapid elevation of chemo/cyto- SDF-1 and VEGF Increase sKitL Plasma Levels
kine levels after BM ablation contributes to MMP-9 If a significant role of MMP-9 activation in the postmyelo-
upregulation, setting the stage for HSC recruitment. suppression process is the release of sKitL, then im-
To determine whether chemo/cytokines induce paired hematopoietic cell mobilization following SDF-1
MMP-9 expression in vivo, we introduced SDF-1, VEGF, and VEGF treatment of MMP-9/ mice could be due to
and G-CSF into wild-type mice. BM of the mice treated their inability to produce sKitL. Indeed, we observed
with SDF-1, VEGF, or G-CSF showed increased immu- increased plasma sKitL levels in MMP-9/ mice after
noreactive MMP-9 on stromal and hematopoietic cells treatment with SDF-1, VEGF, and G-CSF as compared
(Figures 5Bc, d, e, and f). These studies raised the possi- to untreated animals (Figure 6F). This chemo/cytokine-
bility that chemo/cytokine-induced MMP-9 activation induced upregulation of sKitL was impaired in MMP-9/
mediates mobilization of hematopoietic cells. mice. These results highlight the importance of MMP-9-
We found that SDF-1 and VEGF stimulate the release induced sKitL release for hematopoietic recovery.
of pro-MMP-9 and induce migration of human CD34
progenitor and stem cells (5 week cobblestone forming Mobilization of BM-Derived Endothelial
cells [CAFC] and long-term culture initiating cells [LTC- Progenitors Is MMP-9 Dependent
IC]) in a transwell migration assay (Figure 5C). The migra- c-Kit is expressed on BM-derived progenitors that can
tion of CD34 cells was completely blocked by addition give rise to cardiac muscle, skeletal muscle, and endo-
of MPIs (CGS 27023A and 5-phenyl-1,10-phenanthro- thelial cells. Therefore, we asked if MMP-9 plays a more
line). Direct incubation of CD34 cells with MPIs in sus- general role in regulating other tissue-specific stem
pension culture did not alter their proliferation in CAFC cells. Elevation of plasma levels of SDF-1 and VEGF in
or LTC-IC assays (data not shown). These data suggest wild-type mice increased the mobilization of circulating
that chemokines induce the functional expression of endothelial progenitors (CEPs) as assessed by the gen-
eration of late outgrowth endothelial cell colony formingMMP-9 on CD34 cells and their migration.
MMP-9 Regulates the Stem Cell Microenvironment
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Figure 5. Chemo/Cytokines Induce MMP-9 Expression in BM Hematopoietic Cells
(A) MMP-9/ mice were treated with a single dose of 5-FU. At indicated time points, plasma was analyzed for SDF-1 by ELISA (n  6/time
point).
(B) MMP-9/ and MMP-9/ mice received AdSDF-1, AdVEGF, and AdNull vector by a single i.v. injection. BM sections were stained for pro-
MMP-9. MMP-9/ mice treated with G-CSF served as negative control (a and b). BM sections after AdSDF-1 (c and d), AdVEGF (e), and
G-CSF (f) in MMP-9/ mice. Magnification  100 (a and c),  400 (b, d–f).
(C) Human CD34 cells were plated in Matrigel-coated transwells. MPIs (5-phenyl-1,10-phenanthroline and CGS 27023A) or PBS were added
to both chambers. The chemoattractant SDF-1 was added to the lower chamber. Data are shown as a percentage of migrated cells (black
bar). Migrated stem cells assayed as absolute number of CAFC at week 5 (open bar) and of LTC-IC (hatched bar; n  3, *p 0.05 for the
migration of cells treated with/without MPI toward SDF-1).
Insert: Gelatin zymogram of culture supernatants from human CD34 cells stimulated with/without SDF-1 or VEGF in serum-free medium.
Supernatants from CD34 cell cultures showed gelatinolytic activity for pro-MMP-9 (92 kDa).
units (CFU-EC) and the expression of VEGF-receptor-2 strate a key role for MMP-9 to rapidly release the stem
cell-active cytokine sKitL, thereby directing stem and(VEGFR2; Figures 7A and 7B). In contrast, VEGF did not
progenitor cell recruitment and facilitating hematopoi-mobilize CFU-EC or VEGFR2 cells into the circulation
etic reconstitution. This is schematically represented inof wild-type mice treated with MPI (Figures 7A and 7B).
Figure 8. We show that BM suppression results in aSimilarly, VEGF increased the number of CFU-EC in the
timely upregulation of MMP-9 within the BM microenvi-PB (Figure 7C) and VEGFR2 cells in the BM of
ronment with the release of sKitL. Increased bioactiveMMP-9/, but not in MMP-9/mice (Figure 7D). Collec-
sKitL promotes HSC cell cycling and enhances theirtively, these results suggest that MMP-9 activation is
motility, both of which are essential for HSC and progen-required for the recruitment and mobilization of BM-
itor survival and differentiation. MMP-9 activation alsoderived CEPs.
facilitates mobilization of BM repopulating cells into the
peripheral circulation, a process that may be essential
Discussion for reconstitution of the stem cell pool. Collectively,
these data introduce a paradigm in stem and progenitor
Rapid recruitment of HSCs from their quiescent niche cell biology whereby activation of a metalloproteinase
is essential to repopulate progenitors of the myeloid and serves as the decisive checkpoint for the rapid reconsti-
megakaryocytic lineage to avoid life-threatening infec- tution of the hematopoiesis following life-threatening
tion and bleeding after BM suppression. Physiological stressors.
stress induces rapid recruitment of stem cells from their
BM niche with subsequent mobilization to the circula- MMP-9 Alters the Quiescent Stem Cell Niche
tion, where they home to respective organs and either by Releasing sKitL
contribute to restore organ function or regenerate the The HSCs and BM-derived CEPs reside in a microenvi-
ronment where they can readily sense and respond tostem and progenitor cell pool. In this study, we demon-
Cell
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Figure 6. Chemo/Cytokine-Induced HSC Mobilization Is Impaired in MMP-9/ Mice
(A–C) MMP-9/ and MMP-9/ mice were injected i.v. with a single dose of AdSDF-1, AdVEGF, and AdNull vector or s.c. with recombinant
G-CSF from day 0–5 (n  10 mice in each group). Elevated chemokine levels for SDF-1 and VEGF were achieved by adenoviral gene delivery
of SDF-1 and VEGF ([A] and [B], bar graph insert). WBC counts were determined following AdSDF-1 (A), AdVEGF (B), and G-CSF treatment
in MMP-9/ mice (C).
(D) Mobilized PBMCs were plated in a colony assay. The number of mobilized progenitor cells (CFU-C) was determined (n  10, *0.05, **p
0.01) on day 5 (AdSDF-1), on day 3 (AdVEGF), and on day 5 (G-CSF).
(E) PB of MMP-9/ and MMP-9/ mice treated with or without G-CSF was obtained on day 5. PBMCs were transplanted into lethally irradiated
syngeneic animals. Survival of transplanted recipients was monitored (n  8/group, *p 0.001).
(F) Plasma of MMP-9/ and MMP-9/ mice 5 days after G-CSF, AdNull, AdSDF-1, and AdVEGF injection and untreated controls was assayed
for sKitL (n  6/group, *p 0.03).
the stress-induced demands for supporting hematopoi- mains predominantly membrane associated (Huang et
al., 1992). The only enzyme reported to date to cleaveesis and angiogenesis. To meet such a high demand,
rapid availability of cytokines is essential for the recruit- mKitL is a mast cell chymase (Longley et al., 1997). The
extracellular domain of mKitL has two potential consen-ment of quiescent HSCs and CEPs to a permissive niche
where they can proliferate, differentiate, and replenish sus sequences that can be hydrolyzed by MMP-9 (Kridel
et al., 2001). The rapid increase in plasma sKitL levelsthe exhausted progenitor and precursor pool. We show
that this microenvironmental switch depends on the in MMP-9/ mice and the relative deficiency of sKitL
at baseline or after myelosuppression in MMP-9/ miceupregulation of MMP-9 by BM cells, resulting in in-
creased bioavailability of sKitL. strongly suggest that MMP-9 plays a physiological role
in releasing sKitL, setting up the stage for hematopoieticMMP-9 cleaves several cytokines and/or their recep-
tors, a process that can either activate or inactivate the reconstitution.
cytokines (Vu and Werb, 2000). We hypothesized that
active MMP-9 releases membrane-bound KitL (mKitL). Impairment in MMP-9 Mediated Release of sKitL
Results in Delayed Hematopoietic ReconstitutionA precedent for such a process is the MMP-9-induced
VEGF release from the tethered pool within the microen- and Increased Mortality after Myeloablation
What is the role of increased sKitL levels in the contextvironment of developing bone (Engsig et al., 2000) or
within tumors of pancreatic islets (Bergers et al., 2000). of hematopoietic recovery after BM suppression or stem
cell mobilization? Rapid hematopoietic recovery follow-mKitL is a glycoprotein of 248 amino acids that is rapidly
cleaved from the cell to release an active soluble protein ing chemotherapy depends on the ability of quiescent
stem cells to enter cell cycle (Morrison et al., 1997a,of 164 amino acids. In contrast, a glycoprotein of 220
amino acids, which lacks the proteolytic cleavage site 1997b). KitL stands out as the main upmodulator of stem
cell function affecting growth, survival, and/or differenti-encoded by differentially spliced exon 6 sequences, re-
MMP-9 Regulates the Stem Cell Microenvironment
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Figure 7. Endothelial Cell Progenitor Mobilization Is Blocked in MMP-9/ Mice
The number of circulating endothelial progenitor cells (CEPs), represented in in vitro cultures as colony forming units of endothelial cells (CFU-
EC) were determined in the PB of MMP-9/ and MMP-9/ mice three days after injection with AdVEGF, AdSDF-1, AdNull, and G-CSF in the
presence or absence of MPI.
(A and B) CEPs were quantified by the formation of CFU-EC and by VEGFR2 cells detected by FACS. The increase in circulating CFU-EC
in VEGF-treated animals correlated with the number of VEGFR2 cells (*p  0.05).
(C and D) MMP-9/ and MMP-9/ mice were injected i.v. with a single dose of AdVEGF and AdNull vector (n  6/group, *p 0.05). Mobilized
PBMC were assayed for the number of CFU-EC in circulation (C) and the number of VEGFR2 cells in the BM on day 6 after adenoviral
injection (D).
ation of hematopoietic cells and driving hematopoietic stood. Homozygous steel dickie Sld/Sld mice, which lack
mKitL, have defective hematopoiesis under steady-reconstitution after BM ablation. Although MMP-9 null
mice have cell-associated KitL, the low levels of sKitL, state conditions, suggesting that mKitL may play a role
in survival of HSCs. However, since it is difficult to gener-as seen in the MMP-9/ mice, result in delayed entry
of stem cells into the S phase of cell cycle leading to ate transgenic mice completely deficient in sKitL, the
physiological significance of sKitL under steady-statediminished cell motility and differentiation.
The biological significance of sKitL and mKitL in the conditions remains unknown (Tajima et al., 1998). In
accordance with our data, although MMP-9 mediatedregulation of postnatal hematopoiesis is not under-
Figure 8. Functional Anatomy and Recruit-
ment of c-Kit Stem and Progenitor Cells Is
Dictated by MMP-9 Mediated Release of
sKitL
Under steady-state conditions quiescent
c-Kit HSCs and CEPs reside in a niche in
close contact with stromal cells including os-
teoblasts. Membrane-bound cytokines, such
as mKitL not only convey survival signals, but
also support the adhesion of stem cells to the
stroma. BM ablation or chemokine/cytokine
administration induces upregulation of
MMP-9 resulting in the release of sKitL. sKitL
confers signals that enhances mobility of
VEGFR2 endothelial progenitors (CEPs) and
LinSca-1c-Kit repopulating cells, translo-
cating them into a vascular-enriched niche
favoring differentiation and mobilization to
the peripheral circulation.
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release of sKitL may not be required for steady-state phils generates high levels of MMP-9. In another report,
intravenous injection of recombinant MMP-9 into rabbitshematopoiesis, sKitL is essential for the rapid hemato-
poietic reconstitution during the critical pancytopenic produced a rapid, transient neutropenia, followed by a
profound neutrophilia and the appearance of immatureperiod when there is exhaustion of precursor/progenitor
cells. myeloid cells, including blast cells (Masure et al., 1997).
These results can be explained by MMP-9 mediatedDespite germ-free conditions where the 5-FU treated
mice were kept in our studies, the delay in hematopoietic release of sKitL.
We have previously demonstrated that endothelial-recovery was translated into the demise of 72% of the
5-FU-treated MMP-9/ mice, while all of the 5-FU- active cytokines, such as VEGF and SDF-1 induce mobi-
lization of BM repopulating cells (Hattori et al., 2001a,treated MMP-9/ mice survived. We expect that under
nonsterile conditions significantly more of the 5-FU 2001b). Here, we demonstrate that MMPs are necessary
intermediates downstream of these factors. Cytokine-treated MMP-9/ mice would have succumbed to the
complications of prolonged neutropenia and thrombo- induced mobilization of hematopoietic progenitors and
cells with HSC potential was markedly impaired in MPI-cytopenia. These findings underscore the need for rapid
shedding of sKitL in addition to constitutively expressed treated or MMP-9/ mice.
Why are HSCs mobilized after stress? Does it play amKitL to restore hematopoiesis.
In humans, rapid BM recovery after repetitive treat- critical role in reconstituting the stem cell pool, or is it
a coincidental process of moving stem cells out of theirment with chemotherapeutic agents is essential to avoid
morbidity and mortality secondary to prolonged BM quiescent niche? Mobilization of stem and progenitor
cells seems to be essential for reconstitution of the stemsuppression. Indeed, life-threatening infections and
bleeding are direct effects of prolonged chemotherapy- cell pool in murine myelosuppression models. Indeed,
mobilization and localization of BM-derived stem cellsrelated neutropenia and thrombocytopenia. It is con-
ceivable that chronic use of certain chemotherapeutic to the spleen may facilitate the expansion of the stem/
progenitor cell pools. In this regard, MMP-9 activationagents may alter MMP-9 secretion and activation and
therefore, induce long-term BM suppression or disrupt not only promotes trilineage hematopoietic recovery,
but also facilitates mobilization of HSC and CEPs, atrafficking of HSCs contributing to BM failure states. On
the other hand, inhibition of MMP-9 may provide a novel process essential for hematopoietic reconstitution and
replenishment of stem and progenitor cells.mechanism to regulate hematopoiesis in myeloprolifera-
tive disorders.
Endothelial Progenitor Cell Mobilization
Is MMP-9 DependentMMP-9 Activation Enhances Stem
and Progenitor Cell Recruitment BM not only provides a suitable microenvironment for
HSCs, but is also a dispensable reservoir for organ-spe-Upregulation of adhesion molecules and chemokine re-
ceptors on HSCs, progenitors, and CEPs facilitate their cific stem cells for endothelium, muscle, brain, pancreas,
and liver cells (Krause et al., 2001). c-Kit is expressed onrecruitment within the BM followed by mobilization to
the circulation. Our data show that MMP-9 mediated HSCs, CEPs (Peichev et al., 2000), and cardiac precur-
sors (Orlic et al., 2001). Selective recruitment of BM-release of sKitL enhances the motogenic potential of
stem and progenitor cells, translocating them from their derived stem cells is critical for supporting postnatal
organogenesis and tumorigenesis (Coussens et al.,quiescent into a permissive proliferative vascular niche.
sKitL is a potent cytokine that not only increases the 2000; Lyden et al., 2001). We found that mobilization of
both HSCs and VEGFR2 CEPs to the circulation occursmotility of HSC and progenitors within the BM, but also
sets up the stage for hematopoietic cells to be launched in response to VEGF and is MMP-9 dependent. These
data suggest that MMP-9 activation is not only a deci-to the circulation (Long et al., 1992; Papayannopoulou
et al., 1998). Whether sKitL acts as a dominant interfering sive checkpoint for recruitment of HSCs but also other
types of undifferentiated cells, such as endothelial pro-molecule to reverse adhesion of c-Kit HSC and CEPs
to mKitL expressed on stromal cells, or whether it has genitors.
Taken together, these data provide evidence thata direct signaling effect increasing cell motility remains
to be determined. stem and progenitor cell recruitment from the quiescent
niche into a permissive microenvironment followingAfter elimination of the cycling stem cell pool with
5-FU treatment, we observed hematopoietic cell clus- stress depends on MMP-9. This protease acts on differ-
ent levels by directly releasing sKitL, affects cell mobilityters in close contact to osteoblasts (osteoblastic zone)
on day 3 in both wild-type and MMP-9/mice. However, and promotes recruitment of stem and progenitor cells,
thereby enhancing rapid differentiation. Stem cell-stro-at later time points, hematopoietic clusters in MMP-9/
mice did not repopulate the inner vascular zone. Based mal cell interactions are amplified by membrane-
anchored cytokines, by transducing proliferation and/on these results, we postulate that MMP-9 mediated
release of sKitL increases the motogenic potential of or differentiation signals, and by the maintenance of
progenitors in a quiescent state under the constraintsHSCs, shifting HSCs into a vascular enriched microenvi-
ronment where they receive instructions for differentia- of limited growth factor concentrations. It is intriguing
that the conversion of KitL from a membrane-bound,tion and mobilization.
Increased MMP-9 has been detected in the serum of adhesion/survival-promoting molecule to a soluble sur-
vival/motogenic factor by MMP-9 is a critical event inIL-8-treated monkeys and was linked to the mobilization
of progenitor cells (Pruijt et al., 1999). These authors regulating the stem cell niche. Because modulating the
bioavailability of local cytokines changes the HSC fate,hypothesized that the IL-8-induced activation of neutro-
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over a discontinuous gradient using Lympholyte-M (Cedarlane, On-regulators of enzyme activity leading to proteolytic
tario, Canada).cleavage are critical elements in the determination of
Progenitor Assaythe HSC fate. It will be interesting to determine if MMP-9
PBMCs (105 ) were plated in IMDM containing 1.2% methylcellulose
is essential for the recruitment of other stem cells that (Fisher Scientific, NJ), 30% FBS, 5  103 M 2-mercaptoethanol, 2
express c-Kit, and if there is an analogous specific prote- mM L-glutamine, 0.5 mM hemin (Sigma), murine KitL (20 ng/ml),
human erythropoietin (6 U/ml), and murine IL-3 (50 ng/ml). Coloniesase-dependent regulatory process regulating the stem
(50 cells) were scored after 7 days (37C, 5% CO2).cell niche for c-Kit negative stem and progenitor cells.
CFU-S Assay
Mobilized PBMCs (105 /mouse) of chemokine-treated SCID miceExperimental Procedures
were injected i.v. into lethally irradiated syngeneic recipients (9 Gy).
Spleens were removed 12 days later and fixed in Bouin’s solution.Animal Studies
The number of macroscopic spleen colonies was scored.SCID mice, age and sex-matched (7–8 weeks), weight (20 g) were
BM Repopulating Assaypurchased from the Jackson Laboratory (Bar Harbor, ME).
Chemo/cytokine-mobilized PBMCs from SCID mice treated with/MMP-9/ 129Sv mice were generated (Vu et al., 1998) and used
without MPI were collected on day 7. PBMCs from G-CSF-treatedafter at least eight back crosses to CD1 mice. MMP-9/ 129Sv
MMP-9/ and MMP-9/ mice were collected on day 5. Mobilizedmice were obtained by back crossing MMP-9/ 129Sv mice with
PBMCs (105 ) were injected into lethally irradiated syngeneic animalsCD1 mice. Mice were maintained in filtered germ-free air Thorensten
(9.5 Gy). Survival was monitored.units.
Endothelial Progenitor Assay
Circulating BM-derived CEPs were quantified by colony formingAdministration of 5-FU
unit-endothelial cell (CFU-EC) as previously described (Hattori etMMP-9/ and MMP-9/ mice were injected with 5-FU (250 mg/kg
al., 2001a). Mobilized PBMCs were cultured in M199 media (GIBCO-body weight, Pharmacia & Upjohn Company) intravenously (i.v.). At
BRL, Gaithersburg, MD) supplemented with 20% FBS (HyClone,indicated time points, mice were sacrificed. Femurs were flushed
UT), ECGF (30 	g/ml), human FGF-basic (Sigma), and heparin. Afterand BM cells were used for cell cycle analysis or subjected to
5 weeks of culture, adherent cells were scored for colonies (10magnetic bead isolation (MACS; Miltenyi Biotec). Lineage-negative
cells). Endothelial colonies were identified by metabolic uptake ofBM cells were isolated by MACS after labeling the cells with a
DiI-acetylated-LDL (1 	g/ml; PerImmune Inc., Rockville, MD) at 37Cdepletion cocktail of lineage-specific monoclonal antibodies
for 5 hr and visualized by fluorescence microscopy. Number of(mAbs), including CD5, CD45R, CD11b, Gr-1, TER119, and 7/4 (Stem
VEGFR2 cells was quantified by FACS using a Cy2-labeled mAbCell Technology, Canada). Lin cells were MACS isolated with mAb
to VEGFR2 (clone DC101, ImClone, NY; Hattori et al. 2001a).against Sca-1. The separated LinSca-1 BM cells were 96%
positive for Sca-1 (clone E13-161.7; PharMingen, San Diego)
and 99% positive for c-Kit (clone 2B8, Bioscience). Less than 4% In Vitro Assays
of the LinSca-1 cells showed staining for CD11b, CD3, B220, or Murine BM Cultures
Gr-1. For cell cycle analysis, whole BM cells of MMP-9/ and MMP- Murine BM cells (1  106 ) from MMP-9/ and MMP-9/ BM cells
9/ mice were labeled with Sca-1-FITC. LinSca-1 BM cells were isolated after treatment with/without 5-FU were placed in serum-
labeled with c-Kit-FITC. Labeled BM cells and LinSca-1 cells were free medium (X-VIVO-20) overnight. Culture supernatants were ana-
fixed in ice-cold ethanol for 30 min. After RNase treatment (Sigma, lyzed by Western blotting using murine mAb (1 	g/ml) to MMP-9
MO), cells were stained with propidium iodide (Molecular-Probes, (clone 7-11C, Oncogene Research-Products); anti-mouse IgG-con-
Oregon). The DNA content of Sca-1 and LinSca-1c-Kit cells jugated to horseradish peroxidase (1:6000 dilution, Santa Cruz Bio-
was determined by FACS (Coulter flow cytometer). technology, CA) and visualized using ECL chemiluminescence
(Amersham Pharmacia-Biotech).
Mobilization of BM-Derived Cells Stromal Cell Line Cultures
by Adenovirus-Delivered Factors Stromal cells (MS-5) were cultured in serum-free medium, and
Plasma levels of VEGF, SDF-1, and KitL were elevated by using an treated with recombinant active MMP-9 (Oncogene, Boston, MA) or
adenovirus 5 (Ad)-derived E1a-, E3-deficient (E1aE3E4) vector an MPI CGS 27023A for 24 hr.
with an expression cassette in the E1a region containing the trans- Substrate Zymography
gene cDNA and driven by the cytomegalovirus promoter/enhancer Supernatants from human MACS-isolated CD34 (5  103 ) cells
(Hattori et al., 2001b). Mice received the Ad-vector expressing SDF-1 were collected after overnight incubation in serum-free medium
(AdSDF-1) or no transgene (AdNull) at a concentration of 1  109 with/without SDF-1 (150 ng/ml, R&D Systems) or VEGF (50 ng/ml,
plaque forming units (PFU) and Ad-vector expressing sKitL (AdsKitL) PeproTech). MMP activity was determined by gelatin zymography
or VEGF165 (AdVEGF) at a concentration of 1.5 108 PFU. The vector (Lane et al., 2000).
was injected i.v. as a single dose. Recombinant G-CSF (R&D Sys- Immunoassay for Chemokines and Cytokines
tems, MN) was administered s.c. daily from day 0–5 at 50	g/kg body Plasma levels of SDF-1, VEGF, and sKitL were measured using
weight. Recombinant murine KitL (PeproTech, NJ) was injected s.c. commercial available ELISA (R&D Systems).
twice a day at 100 or 200 	g/kg body weight. Immunohistochemistry
CGS 27023A, a potent inhibitor of MMP-9 (IC50  8 nM), MMP-2 BM sections were deparaffinized, rehydrated through an alcohol
(IC50  11 nM), and MMP-3 (IC50  13 nM; Novartis, Basel, Switzer- series, immersed in 0.1% H2O2, and blocked using an Avidin and
land), was injected at 60 mg/kg body weight s.c. every 3 days starting Biotin blocking kit (Vector, Burlingame, CA). For MMP-9 staining, the
from day 0. M.O.M. immunodetection kit (Vector) was used as recommended.
Sections were incubated with MMP-9 mAb (clone 7-11C, Oncogene,
BM Transplantation MA) for 30 min, washed in PBS, incubated with a biotinylated horse
BM cells (3  107 /mouse) from 8-week-old MMP-9/ and MMP- anti-mouse IgG, and incubated for 5 min with A&B reagents (Vector).
9/ mice were injected i.v. into lethally irradiated (9.5 Gy from a Von Willebrand Factor (vWF) immmunohistochemistry was per-
137Cs 
-ray source) MMP-9/ and MMP-9/ mice. Sixteen days formed on deparaffinized sections, treated with 3% H2O2, and incu-
later, mice were treated with 5-FU as described above. Survival was bated with 0.05% pronase E (Sigma). Sections were stained with
monitored. anti-human vWF/HRP (Dako). Sections were developed with 3,3-
diaminobenzidine substrate and counterstained with eosin and he-
matoxylin.Hematopoietic/Endothelial Progenitor and Stem Cell Assays
Peripheral Blood Analysis In Vitro Transmigration through Reconstituted
Basement MembranesBlood was collected with capillary pipettes by retro-orbital bleeding
and WBC counts were determined by using a hemocytometer. CD34 cells from PBMC of normal donors were isolated by MACS
(Miltenyi Biotec) and showed a purity of 95% by FACS. CD34PBMCs were isolated from heparinized blood after centrifugation
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cells were added to 8	m pore matrigel-coated (BD) transwell inserts S., Gardner, R., Neutzel, S., and Sharkis, S.J. (2001). Multi-organ,
multi-lineage engraftment by a single bone marrow-derived stem(Costar, Cambridge, MA). Recombinant SDF-1 (100 ng/ml) was
added to the lower chamber with/without MPIs 5-phenyl-1,10-phen- cell. Cell 105, 369–377.
anthroline (1 mM, Sigma), or CGS 27023A (1 nM, Novartis, Switzer- Kridel, S.J., Chen, E., Kotra, L.P., Howard, E.W., Mobashery, S., and
land) which were added to both chambers. Transmigrated cells were Smith, J.W. (2001). Substrate hydrolysis by matrix metallopro-
quantified, placed in a clonogenic assay and in long-term cultures teinase-9. J. Biol. Chem. 276, 20572–20578.
to measure the number of CAFCs and LTC-ICs (Jo et al., 2000).
Lane, W.J., Dias, S., Hattori, K., Heissig, B., Choy, M., Rabbany,
Statistical Analysis
S.Y., Wood, J., Moore, M.A., and Rafii, S. (2000). Stromal-derived
Results are expressed as mean  standard deviation. Data were
factor 1-induced megakaryocyte migration and platelet production
analyzed using the unpaired two-tailed student’s t test and the log
is dependent on matrix metalloproteinases. Blood 96, 4152–4159.
rank test. P values of  0.05 were considered significant.
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